HuagongsheHuagongshe Chemistry Print Report · For research reference only
3-(N-Acetyl-N-methylamino)pyrrolidine → N-methyl-N-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-yl)acetamide
Participants
| Role | Name | HCID | Charge |
|---|---|---|---|
| Reactant | 3-(N-Acetyl-N-methylamino)pyrrolidine | HCID 13041130 | — |
| Reactant | 4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine | HCID 59605812 | — |
| Product | N-methyl-N-(1-((9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-6-morpholino-9H-purin-8-yl)methyl)pyrrolidin-3-yl)acetamide | HCID 59605585 | — |
Reaction Steps
4-(8-(Bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine (50 mg) was reacted with N-methyl-N-(pyrrolidin-3-yl)acetamide via General Procedure E to give 25.5 mg of 298 following reverse phase purification. MS (Q1) 504.2 (M)+
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| Patent number | US08173650B2 |
| Source dataset | uspto-grants-2012_05 |
| ORD ID | ord-33e672329e89408caf7dee585c4018dc |
| Source note | uspto-grants-2012_05 |